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PURPOSE. Large-scale protein analysis may bring important insights into molecular
changes following branch retinal vein occlusion (BRVO). Using proteomic techniques
this study compared aqueous humor samples from patients with BRVO to age-matched
controls.
METHODS. Aqueous humor samples from treatment naive patients with BRVO complicated
by macular edema (n = 19) and age-matched controls (n = 18) were analyzed with label-
free quantification nano liquid chromatography – tandem mass spectrometry (LFQ nLC-
MS/MS). The severity of macular edema was measured as central retinal thickness (CRT)
with optical coherence tomography. Control samples were obtained prior to cataract
surgery. Proteins were filtered by requiring quantification in at least 50% of the samples
in each group without imputation of missing values. Significantly changed proteins were
identified with a permutation-based calculation with a false discovery rate at 0.05.
RESULTS. In BRVO, 52 proteins were differentially expressed. Regulated proteins were
involved in cell adhesion, coagulation, and acute-phase response. Apolipoprotein C-III,
complement C3, complement C5, complement factor H, fibronectin, and fibrinogen chains
were increased in BRVO and correlated with CRT. Fibronectin also correlated with best
corrected visual acuity (BCVA) and vascular endothelial growth factor (VEGF). Monocyte
differentiation antigen CD14 (CD14) and lipopolysaccharide-binding protein (LBP) were
upregulated in BRVO. Contactin-1 and alpha-enolase were downregulated in BRVO and
correlated negatively with CRT.
CONCLUSIONS. Multiple proteins, including complement factors, fibrinogen chains,
and apolipoprotein C-III, correlated with CRT, indicating a multifactorial response.
Fibronectin correlated with BCVA, CRT, and VEGF. Fibronectin may reflect the severity
of BRVO. The proinflammatory proteins CD14 and LBP were upregulated in BRVO.
Keywords: retina, branch retinal vein occlusion, proteomics, mass spectrometry, macular
edema
Branch retinal vein occlusion (BRVO) is the mostfrequent retinal vascular disease after diabetic retinopa-
thy.1 Macular edema is the most common cause of visual
impairment in BRVO.1 Important elements in the develop-
ment of macular edema secondary to BRVO include vascular
endothelial growth factor (VEGF), VEGF receptor-1 and 2, as
well as an inflammatory response mediated by interleukin-
6, interleukin-8, monocyte chemoattractant protein 1, and
platelet-derived growth factor.2–10 Although this subset of
proteins is well-characterized in BRVO, there is very limited
knowledge about large-scale intraocular protein changes in
samples from humans with BRVO.11
Large-scale protein analyses are effectively performed
with mass spectrometry-based proteomic techniques, which
aim at identifying and quantifying the entire set of proteins
in a given tissue or body fluid.12–16 Proteome studies of
aqueous humor may bring valuable insights into molecu-
lar changes following BRVO.11,17 However, the human aque-
ous proteome of BRVO remains largely unstudied with mass
spectrometry except for a study on aqueous humor from
six BRVO patients, which was published by Yao et al.18 in
2013. With major advances in recent years, proteomic tech-
niques allow for in-depth protein analysis that may elucidate
molecular mechanisms underlying ocular diseases.11–17 In
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TABLE 1. Samples for Proteomic Analysis
BRVO Group Control Group P Value
Number of samples (n) 19 18
Age (years) 70.9 ± 7.8* 72.1 ± 13.6* 0.76
Sex (M/F) 10/9 8/10
Size of macular edema (μm) 519 ± 257* – –
BCVA (logMAR) 0.53 ± 0.39* – –
Patients with retinal area of nonperfusion ≤ 5 disc areas (n) 5 – –
Patients with retinal area of nonperfusion > 5 disc areas (n) 14 – –
* Data are expressed as mean ± standard deviation.
the present study, we used advanced proteomic techniques
to compare 19 aqueous humor samples from patients with
BRVO and macular edema with 18 age-matched controls.
METHODS
Samples
The study was conducted in compliance with the insti-
tutional review board of Kyoto Prefectural University of
Medicine from which approval for the study was obtained
(permission RBMR-C-864-6). The study adhered to the tenets
of the Declaration of Helsinki. Aqueous humor samples from
treatment naive patients with BRVO complicated by macu-
lar edema (n = 19) and age-matched controls (n = 18)
were donated from the biobank of Kyoto Prefectural Univer-
sity Hospital, Kyoto, Japan, for proteomic analysis (Table 1).
Informed consent to use samples from the biobank was
obtained from all patients after explanation of the nature
and possible consequences of the study. Statistical anal-
ysis by the Student’s t-test was used to verify that there
was no statistically significant difference in age between the
BRVO group and the age-matched control group (Table 1).
All patients in the BRVO group had BRVO complicated by
macular edema and were treatment naive. Duration of macu-
lar edema less than 3 months was required. In the BRVO
group, exclusion criteria were glaucoma including neovas-
cular glaucoma, iris rubeosis, hyphema, retinal neovascular-
ization, vitreous hemorrhage, previous retinal photocoagu-
lation, and diabetes mellitus. Patients with BRVO who used
any kind of eye drops 3 months prior to sample collection
were also excluded. Control samples were from age-matched
patients from whom aqueous humor samples were obtained
prior to cataract surgery. Patients in the control group had
no other disease than cataract. Best corrected visual acuity
(BCVA) was measured as the logarithm of the minimum
angle of resolution (logMAR). Swept Source OCT (DRI-OCT
Triton; Topcon, Tokyo, Japan) was used for optical coher-
ence tomography (OCT) examination. The severity of macu-
lar edema was measured as central retinal thickness (CRT)
with the caliper tool of the Topcon OCT software. Fluores-
cein angiography was performed with confocal scanning
laser ophthalmoscope (Heidelberg Retina Angiograph 2;
Heidelberg Engineering, Heidelberg, Germany), and the area
of retinal nonperfusion was measured in disc areas using the
“draw lesion” tool in Heidelberg Retinal Angiography 2.
For confirmation of key findings of the proteomic analy-
sis, additional BRVO samples (n = 15) and control samples
(n = 5) were acquired from the biobank for enzyme-linked
immunosorbent assay (ELISA) (Table 2). Eight samples from
the BRVO group were also used for proteomic analysis.
BRVO samples and control samples were age-matched and
selected according to the inclusion and exclusion criteria
TABLE 2. Samples for Validation of Proteomic Analysis by ELISA
BRVO
Group
Control
Group P Value
Number of samples (n) 15* 5
Age (years) 70.6 ± 11.6† 75.6 ± 6.3† 0.38
Sex (M/F) 8/7 2/3
Size of macular edema (μm) 542 ± 226† – –
BCVA (logMAR) 0.59 ± 0.40† – –
* Samples from eight patients with BRVO were also used for
proteomic analysis.
† Data are expressed as mean ± standard deviation.
stated earlier. Statistical analysis by the Student’s t-test was
used to verify that there was no statistically significant differ-
ence in age between the BRVO group and the age-matched
control group (Table 2).
Sample Preparation for Mass Spectrometry
Samples were stored at −80°C until preparation was initi-
ated. Protein concentrations were measured with an infrared
spectrometer (Direct Detect, Darmstadt, Germany). Samples
were prepared according to the S-Trap Micro spin column
digestion protocol from ProtiFi (Huntington, NY, USA). The
volume of each sample was measured, and an equal volume
of 2 × SDS lysis buffer (10% SDS, 100 mM triethylammo-
nium bicarbonate [TEAB], pH 7.55) was added. The samples
were centrifuged at 13.000g for 8 minutes. Disulfide bonds
were reduced by adding tris(2-carboxyethyl)phosphine
hydrochloride (TCEP) to the protein solution in SDS to
a final concentration of 10 mM, followed by heating for
10 minutes at 95°C. The protein solution was cooled to room
temperature. Cysteines were alkylated by adding iodoac-
etamide to a final concentration of 40 mM. To the SDS lysate,
12% aqueous phosphoric acid at 1:10 was added to a final
concentration of 1.2% phosphoric acid. S-Trap buffer (90%
methanol, 100 mM TEAB) was added. The buffer mixture
was transferred into a microcolumn followed by centrifu-
gation at 4000g until the buffer had passed through the S-
Trap column. S-Trap binding buffer was added, followed by
centrifugation at 4000g. Washing with the S-Trap binding
buffer was performed three times. The S-Trap microcolumn
was moved to a new 1.7 mL sample tube for digestion. A
total of 20 μL digestion buffer was added into the top of the
microcolumn. The column was incubated overnight at 37°C.
Peptides were eluted first with 40 μL of 50 mM TEAB
and then with 0.2% formic acid. Elutions were centrifuged
at 4000g. Hydrophobic peptides were recovered with an
elution of 35 μL 50% acetonitrile containing 0.2% formic
acid. Elutions were pooled. The peptide concentration was
measured with a fluorescence-based technique with trypto-
phan used as a standard with an excitation at 295 nm and
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emission at 350 nm as previously described.19 Each sample
was dried in a vacuum centrifuge and stored at −80°C.
Quantitative Mass Spectrometry by Label-Free
Quantification Nano Liquid Chromatography –
Tandem Mass Spectrometry (LFQ nLC-MS/MS)
Samples were resuspended in 0.1% formic acid and analyzed
with LFQ nLC-MS/MS. Of each sample, 0.7 to 1.0 μg was
analyzed in triplicates. Mass spectrometry was performed
on an Orbitrap Fusion Tribrid mass spectrometer (Thermo
Fisher Scientific Instruments, Waltham, MA, USA) coupled
to a Dionex UltiMate 3000 RSLC nano system (Thermo
Fisher Scientific Instruments, Waltham, MA, USA). The mass
spectrometer was equipped with an EasySpray ion source
(Thermo Fisher Scientific Instruments). Liquid chromatog-
raphy and label-free quantification (LFQ) were performed
as described in a recent article20 with few modifications.
The orbitrap scan range (m/z) was 375 to 1500. The elution
gradient was 3h, established by mixing buffer A (99.9%
water and 0.1% formic acid) and buffer B (99.9% acetonitrile
and 1% formic acid). Using the MaxQuant software version
1.6.6.0 (Max Planck Institute of Biochemistry, Martinsried,
Germany; https://maxquant.net/maxquant/) for LFQ analy-
sis,21 raw data files were searched against the UniProt Homo
sapiens database (www.uniprot.org) downloaded on August
10, 2019. Settings for the database search were published in
a previous work.20 Unfiltered results of the database search
are available in Supplementary File S1.
Mass spectrometry data were further processed with
Perseus software version 1.6.2.3 (Max Planck Institute of
Biochemistry, Martinsried, Germany; https://maxquant.net/
perseus/) to remove poorly identified proteins as described
in a previous article.22 LFQ values were log2 transformed,
and mean LFQ values were calculated. At least two unique
peptides were required for successful protein identification.
Proteins were required to be successfully identified and
quantified in at least 50% of the samples in each group. The
median technical coefficient of variation was calculated for
each of the proteins in each sample. The mean value for the
samples was 11.3% (range, 6.49%–16.1%).
Statistics
Statistical analysis was performed on proteins that were
successfully identified and quantified in at least 50% of the
samples in the BRVO group and 50% of the samples in
the control group. No imputation of missing values was
performed prior to statistical analysis. Statistical analysis by
the Student’s t-test was conducted in Perseus to compare
BRVO with controls. Furthermore, a subgroup analysis was
performed to compare BRVO with greater than 5 disc areas
of retinal nonperfusion and BRVO with less than or equal to
5 disc areas of retinal nonperfusion. Correction for multiple
hypothesis testing was performed using the permutation-
based method23 in Perseus with the number of random-
izations set to 250 and an S0 parameter of 0.1. The false
discovery rate was set to 0.05. CRT values were log10 trans-
formed prior to calculation of correlations to make the CRT
values normally distributed. Correlations were calculated in
STATA 16.0 (StataCorp, College Station, TX, USA) using Pear-
son’s correlation coefficient (r). Correlations were consid-
ered statistically significant if P <0.05. Two-way scatter plots
with prediction from a linear regression were created with
STATA 16.0.
Bioinformatic analysis of statistically significantly
changed proteins was performed with GeneCodis soft-
ware24–26 (https://genecodis.genyo.es/) as previously
described.27 Cluster analysis of statistically significantly
regulated proteins was performed with STRING 11.0
(string-db.org).28–30 If more than one protein was listed in
the IDs, the first listed UniProt ID was used for STRING
analysis. If an isoform was not recognized by STRING,
the regular UniProt ID without isoform was used. Cluster
analysis was performed with the Markov Cluster Algorithm
set to 2.
Enzyme-Linked Immunosorbent Assay (ELISA)
Enzyme-Linked Immunosorbent Assay (ELISA) was
performed to measure aqueous concentrations of fibronectin
and VEGF in 15 BRVO samples and 5 controls (Table 2).
ELISA was conducted with the ab219046 Human Fibronectin
SimpleStep ELISA kit (Abcam, UK)31,32 and the ab222510
Human VEGF SimpleStep ELISA Kit (Abcam, UK).33 Samples
for fibronectin quantification were diluted 1:250, and
samples for VEGF quantification were diluted 1:2. Assay
preparation was performed according to the manufacturer’s
instructions. A volume of 50 μL of standard or sample was
added to the wells following addition of 50 μL antibody
solution (1:10 capture antibody solution and 1:10 detector
antibody in Antibody Diluent 4BR from the kit). The solu-
tions were incubated for 1 hour at room temperature on a
plate shaker set to 480 rpm. Each well was washed with
3 × 350 μL wash buffer (1:10 Wash Buffer PT 10X from
ELISA kit, Abcam, UK, in deionized water). A volume of
100 μL of TMB Development Solution (Abcam, UK) was
added to each well followed by incubation for 10 minutes
in the dark on a plate shaker set to 480 rpm. A volume
of 100 μL of Stop Solution (provided in kit) was added to
each well and the plate was shaken on a plate shaker for
1 minute. The optical density was recorded at 450 nm. The
Student’s t-test and Pearson’s correlation coefficient (r) were
used for statistical analysis of the ELISA data. Differences
and correlations were considered statistically significant if
P <0.05. Two-way scatter plots based on ELISA data with
prediction from a linear regression were created in STATA
16.0.
RESULTS
A total of 1403 proteins were successfully identified in the
combined set of aqueous samples (Supplementary File S2).
A total of 242 aqueous humor proteins were successfully
identified and quantified in at least 50% of the samples in
each group (Supplementary File S3) and statistical analysis
was performed on these proteins.
After correction for multiple hypothesis testing, a total
of 52 proteins were statistically significantly changed in
content in BRVO compared with controls (Table 3, Fig. 1A).
Among the 52 proteins that were changed in content, 26
proteins were increased in content following BRVO,whereas
another 26 proteins were decreased in content in BRVO
(Table 3).
Proteins that were changed in expression level in
BRVO compared with controls were involved in cell
adhesion, blood coagulation, platelet activation, and
platelet degranulation (Fig. 2). BRVO was also associ-
ated with response to lipopolysaccharide, chemotaxis, and
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TABLE 3. Statistically Significantly Regulated Proteins in BRVO Versus Controls
Protein ID Protein Name Gene Name P Value
Fold Change
BRVO/Control
P02675 Fibrinogen beta chain FGB 1.92 × 10−9 17.32
P02679 Fibrinogen gamma chain FGG 1.16 × 10−8 6.89
P02671 Fibrinogen alpha chain FGA 1.72 × 10−7 5.25
P02751-3 Fibronectin FN1 1.10 × 10−6 2.80
P02656 Apolipoprotein C-III APOC3 0.00095 2.47
P01031 Complement C5 C5 6.92 × 10−5 1.75
P01861 Ig gamma-4 chain C region IGHG4 0.031 1.74
P08603 Complement factor H CFH 2.51 × 10−6 1.73
P04004 Vitronectin VTN 0.00074 1.72
P24592 Insulin-like growth factor-binding protein 6 IGFBP6 0.016 1.67
P02749 Beta-2-glycoprotein 1 APOH 3.14 × 10−5 1.67
P02746 Complement C1q subcomponent subunit B C1QB 0.0081 1.61
P02753 Retinol-binding protein 4 RBP4 0.0018 1.60
P06727 Apolipoprotein A-IV APOA4 0.0067 1.55
P36222 Chitinase-3-like protein 1 CHI3L1 0.0071 1.54
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 ITIH1 0.012 1.53
P05546 Heparin cofactor 2 SERPIND1 0.00043 1.50
P08571 Monocyte differentiation antigen CD14 CD14 3.23 × 10−5 1.49
P05090 Apolipoprotein D APOD 0.0036 1.49
P18428 Lipopolysaccharide-binding protein LBP 0.0022 1.48
Q14520 Hyaluronan-binding protein 2 chain HABP2 0.0010 1.44
P00734 Prothrombin F2 0.00030 1.42
P01042 Kininogen-1 KNG1 0.0031 1.40
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 0.0059 1.39
P01024 Complement C3 C3 0.0010 1.38
P01023 Alpha-2-macroglobulin A2M 0.00079 1.37
Q8IZJ3-2 C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 CPAMD8 0.0023 0.78
P13473 Lysosome-associated membrane glycoprotein 2 LAMP2 0.0037 0.72
P07711 Cathepsin L1 CTSL 0.0020 0.71
Q86UX2 Inter-alpha-trypsin inhibitor heavy chain H5 ITIH5 0.0052 0.70
Q12860 Contactin-1 CNTN1 0.0011 0.68
Q08629 Testican-1 SPOCK1 0.0070 0.67
O75326 Semaphorin-7A SEMA7A 0.018 0.67
Q14515-2 SPARC-like protein 1 SPARCL1 0.010 0.67
P13591 Neural cell adhesion molecule 1 NCAM1 0.0030 0.66
P35555 Fibrillin-1 FBN1 0.020 0.65
Q13822 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 ENPP2 0.00015 0.65
Q02413 Desmoglein-1 DSG1 0.013 0.65
P98164 Low-density lipoprotein receptor-related protein 2 LRP2 0.00020 0.64
O94985-2 Calsyntenin-1 CLSTN1 0.0013 0.63
P78509-3 Reelin RELN 0.016 0.61
Q99574 Neuroserpin SERPINI1 0.0027 0.61
Q08380 Galectin-3-binding protein LGALS3BP 0.00029 0.58
P98160 Basement membrane-specific heparan sulfate proteoglycan core protein HSPG2 0.011 0.57
P06733 Alpha-enolase ENO1 0.028 0.55
Q06481 Amyloid-like protein 2 APLP2 4.32 × 10−5 0.49
Q01469 Fatty acid-binding protein, epidermal FABP5 0.013 0.45
P55083 Microfibril-associated glycoprotein 4 MFAP4 0.00028 0.44
P22914 Beta-crystallin S CRYGS 0.00036 0.37
P31151 Protein S100-A7 S100A7 0.033 0.34
P06702 Protein S100-A9 S100A9 0.015 0.31
P05109 Protein S100-A8 S100A8 0.030 0.30
acute-phase response (Fig. 2). Proteins with cell adhesion
features included fibronectin, hyaluronan-binding protein
2 chain, testican-1, microfibrillar-associated protein 4,
neural cell adhesion molecule 1, contactin-1, calsyntenin-1,
galectin-3-binding protein, and reelin. Proteins involved in
response to lipopolysaccharide included S100A7, S100A8,
S100A9, lipopolysaccharide-binding protein (LBP), and
monocyte differentiation antigen CD14 (CD14). Proteins
with chemotactic features included complement C5, S100A8,
S100A9, ectonucleotide pyrophosphatase, and heparin
cofactor 2. LBP, fibronectin, prothrombin, and inter-alpha-
trypsin inhibitor heavy chain H4 were identified as acute-
phase response proteins.
STRING cluster analysis revealed a major cluster
of proteins consisting of fibronectin, fibrinogen chains,
complement factors, and apolipoproteins (Fig. 3). Another
cluster consisted of S100A7, S100A8, S100A9, CD14, LBP,
and complement C1q subcomponent subunit B (Fig. 3).
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FIGURE 1. Volcano plots. (A) Log2 transformed abundance ratios for each protein are plotted on the x-axis. Negative log10 transformed P
values are plotted on the y-axis. A false discovery rate of 0.05 was applied. Statistically significantly changed proteins are localized above
the full curves. (A) BRVO versus age-matched control samples. A total of 52 statistically significantly changed proteins (blue squares) were
identified. (B) BRVO with greater than 5 disc areas of retinal nonperfusion versus BRVO with less than or equal to 5 disc areas of retinal
nonperfusion. A total of 31 significantly changed proteins (blue squares) were identified.
FIGURE 2. Regulated biological processes in BRVO compared with controls. Numbers refer to the number of proteins that represent a given
biological process.
Furthermore, a cluster of reelin, neural cell adhesion
molecule 1, and contactin-1 was identified.
Eleven proteins were positively correlated to severity of
macular edema, whereas two proteins were negatively corre-
lated to severity of macular edema (Table 4, Figs. 4, 5).
Proteins that were positively correlated to CRT included
apolipoprotein C-III; complement C3; complement C5;
complement factor H; fibrinogen chains α, β, and γ ;
fibronectin; heparin cofactor 2; as well as inter-alpha-trypsin
inhibitor chain H1; and chain H4 (Table 4, Figs. 4, 5). Alpha-
enolase and contactin-1 were negatively correlated to CRT
(Table 4, Figs. 4K, 4L).
Proteomic analysis revealed an increased level of
fibronectin in BRVO compared with controls (fold change =
2.80, P = 0.0000011) (Table 3; Fig. 5A). ELISA confirmed that
fibronectin was significantly elevated in BRVO (0.10 μg/mL)
compared with control subjects (0.022 μg/mL) (P = 0.011)
(Fig. 5B). Proteomic analysis identified a correlation between
aqueous fibronectin and BCVA (r = 0.46; P = 0.049)
(Fig. 5C) (Supplementary File S4). The correlation between
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FIGURE 3. STRING cluster analysis of regulated proteins in BRVO compared with controls. A major cluster (red nodes) was formed by
fibrinogen chains (FGA, FGB, FGG), fibronectin (FN1), apolipoproteins (APOA4, APOC3, APOD), and complement factors (C3, C5, CFH).
Another cluster (yellow nodes) was formed by complement C1q subcomponent subunit B (C1QB), monocyte differentiation antigen CD14
(CD14), lipopolysaccharide binding protein (LBP), S100A7, S100A8, and S100A9.
fibronectin and BCVA was confirmed with ELISA (r =
0.56; P = 0.032) (Fig. 5D). Proteome analysis identified
a statistically significant correlation between fibronectin
and the severity of macular edema measured as CRT
(r = 0.60; P = 0.0061) (Table 4; Fig. 5E). This correla-
tion was confirmed with ELISA (r = 0.53; P = 0.042)
(Fig. 5F). Aqueous fibronectin correlated with VEGF in
the BRVO samples (r = 0.70; P = 0.0039) (Fig. 6)
(Supplementary File S5).
Subgroup analysis revealed that the aqueous fibronectin
content was higher in BRVO with greater than 5 disc areas
of retinal nonperfusion compared with BRVO with less than
or equal to 5 disc areas of retinal nonperfusion (fold change
= 2.88; P = 0.00013) (Fig. 1B, Table 5). A total of 31 proteins
were significantly different in BRVO with greater than 5 disc
areas of nonperfusion compared with BRVO with less than
or equal to 5 disc areas of nonperfusion (Fig. 1B, Table 5).
Patients with BRVO and greater than 5 disc areas of
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TABLE 4. Correlations Between Proteomic Data and Severity of Macular Edema
Protein ID Protein Name Correlation, r P Value
P02671 Fibrinogen alpha chain 0.68 0.0013
P02679 Fibrinogen gamma chain 0.67 0.0018
P02675 Fibrinogen beta chain 0.64 0.0029
P02751-3 Fibronectin 0.60 0.0061
P02656 Apolipoprotein C-III 0.54 0.018
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 0.54 0.018
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 0.52 0.022
P08603 Complement factor H 0.51 0.027
P01024 Complement C3 0.47 0.041
P01031 Complement C5 0.47 0.044
P05546 Heparin cofactor 2 0.46 0.049
Q12860 Contactin-1 −0.50 0.029
P06733 Alpha-enolase −0.52 0.023
retinal nonperfusion had higher aqueous levels of fibrinogen
chains, apolipoprotein C-III, and apolipoprotein A-IV, and
lower aqueous levels of amyloid-like protein 2, contactin-1,
reelin, and alpha-enolase (Table 5).
DISCUSSION
The presented study aimed at identifying large-scale protein
changes in aqueous humor from patients with BRVO giving
insights into intraocular molecular changes of the condition.
A multitude of proteins were regulated in BRVO compared
with age-matched controls. Protein changes were generally
more pronounced in BRVO with greater than 5 disc areas of
retinal nonperfusion. Multiple proteins were correlated to
severity of macular edema indicating a multifactorial nature
of the condition.
Fibronectin correlated with BCVA and severity of macu-
lar edema. Fibronectin is a 230 to 270 kDa glycoprotein
that exists in a soluble form and an insoluble form.34–36 The
soluble form in the aqueous humor regulates thrombosis
and accelerates wound healing.35,36 At the wall of injured
vessels the soluble form of fibronectin is rapidly deposited
and promotes platelet aggregation when linked with fibrin.37
Our data indicated that the increased level of fibronectin was
associated with retinal ischemia as the content of fibronectin
was higher in BRVO with greater than 5 disc areas of reti-
nal nonperfusion. The correlation between fibronectin and
BCVA may be explained by the fact that fibronectin was asso-
ciated with severity of macular edema and retinal nonperfu-
sion, which are complications that cause visual impairment
in BRVO. A strong correlation between fibronectin and VEGF
was observed in BRVO. The increased level of fibronectin in
BRVO may reflect a stage of increased VEGF-driven vascular
permeability with leakage of fibronectin. In summary, aque-
ous fibronectin may be an indicator of the severity of BRVO.
The plasma proteins, such as fibrinogen chains,
apolipoproteins, and complement factors, were upregu-
lated in BRVO and correlated with severity of macular
edema. The upregulation of the mentioned plasma proteins
may represent an activation of the coagulation cascade,
as well as a disruption of the blood-retinal barrier that
results in leakage of plasma proteins.11,17 Patients with
BRVO and greater than 5 disc areas of retinal nonperfu-
sion had higher levels of fibrinogen chains, apolipopro-
teins, and complement factors, which may be explained
by increased vascular permeability due to ischemia.9,10,38,39
BRVO was associated with regulation of proteins involved in
“response to lipopolysaccharide,” including the proinflam-
matory proteins LBP, CD14, S100A7, S100A8, and S100A9
(Fig. 2). Lipopolysaccharide is the major component of the
outer membrane of gram-negative bacteria. Recognition of
lipopolysaccharide requires LBP, CD14, and Toll-like recep-
tor 4 (TLR4) that have regulatory functions in the innate
immune system.40,41 LBP and CD14 may contribute to the
inflammatory response in BRVO, but did not correlate with
severity of macular edema and BCVA.
S100A7, S100A8, and S100A9 belong to the S100 protein
family of small calcium-binding proteins42 that contribute to
lipopolysaccharide response in a TLR4 dependent manner.42
We have previously suggested that proteins of the S100
family are regulated in retinal vein occlusion22 and our study
indicates that the turnover of S100 proteins is altered in
BRVO. However, the S100 proteins did not correlate with
CRT and BCVA, and our data does not provide an underly-
ing explanation for the S100 regulation.
Alpha-enolase and contactin-1 were negatively corre-
lated to CRT. BRVO patients with greater than 5 disc diam-
eters of retinal nonperfusion had lower levels of both
proteins, indicating that their regulation is related to reti-
nal ischemia. Alpha-enolase is a glycolytic enzyme known
to be expressed in the cytoplasm and on cell membranes
of retinal ganglion cells, Müller cells, cones, and rods.43
Changes in retinal alpha-enolase have been observed follow-
ing experimental retinal detachment,44 suggesting that the
protein is sensitive to retinal stress. Contactin-1 is a cell adhe-
sion protein involved in axonal organization in early central
nervous system development.45 Retinal contactin-1 has been
found to be downregulated following hyperglycemia,46
indicating that contactin-1 is downregulated in retinal
stress.
Arterial hypertension is a well-documented risk factor
in BRVO.47 It is a limitation of this study that data on
arterial hypertension were not available for patients who
donated aqueous samples to the biobank. Although our
study achieved good coverage of the aqueous proteome,
detection of low abundance proteins remains a challenge in
discovery-type proteomics.11,17 For example, low-abundant
proteins, such as VEGF, interleukin-6, and interleukin-8,
were not identified in our proteome analysis and VEGF
quantification with ELISA was necessary. Detection of
low abundance proteins with discovery-type proteomics is
limited by a number of factors including sample complex-
ity, technical variation, and fragmentation efficiency. Sample
complexity with high dynamic ranges of protein abun-
dances makes detection of low-abundant proteins difficult as
protein abundances may stretch over 13 orders of magnitude
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FIGURE 4. Correlations between aqueous proteins and severity of macular edema measured as central retinal thickness (CRT). CRT values are
log10 transformed to obtain normal distribution. LFQ values denote the contents of the proteins measured by mass spectrometry. Correlations
are calculated as Pearson’s correlation coefficient (r). (A–J) Proteins that were significantly positively correlated to severity of macular edema.
(K, L) Alpha-enolase and contactin-1 were negatively correlated with the severity of macular edema.
depending on the material under study.48 Low abundance
proteins tend to yield larger spectral count variation result-
ing in underestimation of differences in expression level.49
Fragmentation efficiency of tryptic peptides remains a limit-
ing factor in identification of lowly abundant proteins.48
Furthermore, low-abundant proteins with low molecular
weight, for example interleukin-8, yield very few tryptic
peptides, which makes them complicated to identify with
mass spectrometry.50
The sample material is another limitation of our study.
Key proteins identified with proteomic techniques may
correlate with growth factors and cytokines known to be
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FIGURE 5. Fibronectin in BRVO. LFQ values denote the content of fibronectin measured in proteomic analysis by mass spectrometry.
Correlations are calculated as Pearson’s correlation coefficient (r). (A) Proteomic analysis identified an increased content of fibronectin in
BRVO compared with controls. (B) The increased content of fibronectin in BRVO was confirmed with ELISA. (C) Fibronectin quantified with
proteomic analysis correlated with BCVA. (D) ELISA analysis confirmed the correlation between fibronectin and BCVA. (E) Fibronectin quan-
tified with proteomic analysis correlated with severity of macular edema. (F) ELISA analysis confirmed the correlation between fibronectin
and severity of macular edema.
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FIGURE 6. ELISA analysis revealed a significant correlation between
fibronectin and VEGF in BRVO.
associated with macular edema in BRVO. For example, the
samples could also have been screened for inflammatory
proteins, such as interleukin-6 and interleukin-8. Owing to
the low volume and the low protein concentration of the
aqueous samples, we only had sufficient sample material to
verify the correlation between fibronectin and VEGF.
CONCLUSIONS
BRVO was associated with multiple aqueous protein
changes. Proteome changes were more pronounced in
BRVO with greater than 5 disc areas of retinal nonper-
fusion. Fibronectin was increased in BRVO and higher in
BRVO with greater than 5 disc areas of retinal nonperfu-
sion. Fibronectin correlated with BCVA, severity of macu-
lar edema and VEGF. Our findings suggest that aqueous
fibronectin may reflect severity and vascular permeability
in BRVO. Multiple proteins were correlated to the size of
macular edema indicating that macular edema is a multifac-
torial complication. The plasma proteins apolipoprotein C-
III, complement C3, complement C5, complement factor H,
and fibrinogen chains were increased in BRVO and corre-
lated with severity of macular edema. Alpha-enolase and
contactin-1 were negatively correlated with severity of macu-
lar edema. Our study indicated that the expression of alpha-
enolase and contactin-1 is related to retinal nonperfusion.
The proinflammatory proteins LBP, CD14, S100A7, S100A8,
and S100A9 were regulated in BRVO and may contribute to
an inflammatory response in BRVO.
TABLE 5. BRVO with Greater Than 5 Disc Areas of Retinal Nonperfusion Versus BRVO with Less Than or Equal to 5 Disc Areas of Retinal
Nonperfusion
Protein ID Protein Name Gene Name P Value
Fold Change
Ischemia/Nonischemia
P02675 Fibrinogen beta chain FGB 1.86 × 10−5 5.18
P02679 Fibrinogen gamma chain FGG 1.60 × 10−5 4.16
P02656 Apolipoprotein C-III APOC3 0.00014 4.06
P02671 Fibrinogen alpha chain FGA 0.0003 3.83
P68871 Hemoglobin subunit beta HBB 0.0099 3.67
P02751-3 Fibronectin FN1 0.00013 2.88
P01876 Ig alpha-1 chain C region IGHA1 0.0023 2.55
P27169 Serum paraoxonase/arylesterase 1 PON1 0.00089 2.12
P06727 Apolipoprotein A-IV APOA4 0.0037 2.07
P02746 Complement C1q subcomponent subunit B C1QB 4.13 × 10−5 1.98
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 ITIH1 0.00017 1.98
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2 0.0015 1.84
P02647 Apolipoprotein A-I APOA1 0.0023 1.71
P08603 Complement factor H CFH 4.41 × 10−5 1.65
P01011 Alpha-1-antichymotrypsin SERPINA3 2.84 × 10−5 1.59
P02749 Beta-2-glycoprotein 1 APOH 0.0025 1.59
Q96IY4 Carboxypeptidase B2 CPB2 0.00092 1.55
P00747 Plasminogen PLG 0.0016 1.51
P01024 Complement C3 chain C3 0.00054 1.50
P05546 Heparin cofactor 2 SERPIND1 0.0012 1.50
P13473 Lysosome-associated membrane glycoprotein 2 LAMP2 0.0011 0.66
P30086 Phosphatidylethanolamine-binding protein 1 PEBP1 0.004 0.64
Q92520 Protein FAM3C FAM3C 0.0064 0.58
Q12860 Contactin-1 CNTN1 0.0017 0.55
Q15582 Transforming growth factor-beta-induced protein ig-h3 TGFBI 0.0028 0.53
Neural cell adhesion molecule 1 NCAM1 0.0043 0.53
Q9NQ79 Cartilage acidic protein 1 CRTAC1 5.73 × 10−5 0.5
P51693 Amyloid-like protein 1 APLP1 0.00051 0.47
Q06481 Amyloid-like protein 2 APLP2 0.0051 0.45
P78509 Reelin RELN 0.0021 0.37
P06733 Alpha-enolase ENO1 0.0048 0.29
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